Blood Coagulation & Fibrinolysis最新文献_第3页

Time-in-therapeutic range falls as the target international normalized ratio range increases in patients on warfarin. 华法林患者的治疗时间范围随着目标国际标准化比率范围的增加而下降。

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-04-01 Epub Date: 2025-02-05 DOI: 10.1097/MBC.0000000000001347

Imran Malik, Paul Priest, Ian Jennings, Keith Gomez

{"title":"Time-in-therapeutic range falls as the target international normalized ratio range increases in patients on warfarin.","authors":"Imran Malik, Paul Priest, Ian Jennings, Keith Gomez","doi":"10.1097/MBC.0000000000001347","DOIUrl":"10.1097/MBC.0000000000001347","url":null,"abstract":"The main objective was to assess whether the time-in-therapeutic range (TTR) in patients on warfarin is affected by the international normalized ratio (INR) range. We also evaluated whether the performance of the INR is negatively impacted as its absolute value increases. First, we extracted key performance indicators of the INR from 22 surveys of the UK National External Quality Assurance Scheme (NEQAS). We then analysed TTR in 6584 warfarin monitoring episodes that were categorized by range and indication. NEQAS surveys in which the sample INR was above 3.0 had more participants outwith consensus with higher coefficient of variation and standard error mean. The outwith consensus percentage was correlated with the mean reported INR value. In warfarinised patients, we found that the TTR was lower at INR ranges above the standard 2.0 to 3.0. We concluded that the performance of the INR assay decreases at higher values. Furthermore, increasing the INR range above the standard 2.0 to 3.0 in warfarinised patients has an adverse effect on TTR. This is important because the INR range may be increased to try and improve efficacy, whereas these data suggest that it may have the opposite effect.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":"78-81"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CRISPR/Cas9 mediated generation of zebrafish f9a mutant as a model for hemophilia B. CRISPR/Cas9介导的斑马鱼f9a突变体作为B型血友病模型的产生

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-04-01 Epub Date: 2025-03-19 DOI: 10.1097/MBC.0000000000001355

Sanchi Dhinoja, Ayah Al Qaryoute, Afnan Deebani, Anthony De Maria, Pudur Jagadeeswaran

{"title":"CRISPR/Cas9 mediated generation of zebrafish f9a mutant as a model for hemophilia B.","authors":"Sanchi Dhinoja, Ayah Al Qaryoute, Afnan Deebani, Anthony De Maria, Pudur Jagadeeswaran","doi":"10.1097/MBC.0000000000001355","DOIUrl":"10.1097/MBC.0000000000001355","url":null,"abstract":"Aim: This study aimed to develop a zebrafish model for hemophilia B by creating a f9a knockout, as f9a has previously demonstrated functional similarity to human Factor IX.Methods: Using CRISPR/Cas9 technology, two gRNAs targeting exon 8 of the f9a gene, were injected along with Cas9 protein into single-cell zebrafish wild-type embryos. DNA was harvested from the tail tips of the resulting adult zebrafish and screened for mutations using PCR. The founder mutant was crossed with wild-type fish to confirm heritability and subsequently reared to homozygosity. Homozygous mutants were analyzed through quantitative RT-PCR and Western blot to assess f9a RNA and F9a protein levels, respectively. Functional assays like kinetic partial thromboplastin time (kPTT), bleeding assay in adult mutants, and venous laser injury on mutant larvae were performed to assess the hemostatic role.Results: Around 61 adults from the CRISPR/Cas9 knockouts were screened, which resulted in a mutant line with a 72 bp deletion in the exon 8 encoding catalytic domain. Quantitative RT-PCR and Western Blot analysis showed reduced levels of f9a RNA and F9a protein in the homozygous mutants compared to wild-type siblings. At five dpf, f9a homozygous mutant larvae demonstrated prolonged venous occlusion times in a laser injury assay. Additionally, plasma from the mutants displayed delayed fibrin formation in kPTT assays and exhibited increased bleeding after mechanical injury.Conclusion: This study created a zebrafish f9a knockout model that mimics the bleeding phenotype observed in hemophilia B patients, which will be valuable for evaluating novel therapeutic approaches for hemophilia B.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":"90-98"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of cytochrome P-450 3A4 enzyme/P-glycoprotein inducing antiseizure medications on direct oral anticoagulant therapy. 细胞色素P-450 3A4酶/ p -糖蛋白诱导抗癫痫药物对直接口服抗凝治疗的影响。

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-04-01 Epub Date: 2025-01-22 DOI: 10.1097/MBC.0000000000001342

Sean M McNary, Madalyn Kuhlenberg, Lucia F Basilio, Nathan P Clark, Rita L Hui, Fang Niu, Thomas Delate

{"title":"Impact of cytochrome P-450 3A4 enzyme/P-glycoprotein inducing antiseizure medications on direct oral anticoagulant therapy.","authors":"Sean M McNary, Madalyn Kuhlenberg, Lucia F Basilio, Nathan P Clark, Rita L Hui, Fang Niu, Thomas Delate","doi":"10.1097/MBC.0000000000001342","DOIUrl":"10.1097/MBC.0000000000001342","url":null,"abstract":"Objectives: Concomitant use of cytochrome P-450 and P-glycoprotein (CYP 3A4/P-gp) inducing antiseizure medications and direct oral anticoagulants (DOAC) may result in reduced DOAC effectiveness, but study results are inconsistent and of variable quality. The purpose of this study was to assess the safety of concomitant CYP 3A4/P-gp inducing antiseizure medications and DOAC use.Methods: This was a retrospective cohort study of adult patients who were newly, concomitantly receiving a DOAC (apixaban, dabigatran, or rivaroxaban) and either a CYP 3A4/P-gp inducer (carbamazepine, phenytoin, phenobarbital, or primidone) or noninducer (gabapentin). The primary outcome was the occurrence of a thromboembolic complication, defined as the composite of ischemic stroke and systemic embolism (S/SE) and venous thromboembolism (VTE). Secondary outcomes included the components of the primary composite as well as all-cause mortality and clinically relevant bleeding. Adjusted multivariate proportional hazards modeling was used to compare outcomes for each DOAC individually in the inducer and noninducer groups.Results: There were 1843 and 14 647 patients who received a DOAC plus a CYP3A4/P-gp inducer and noninducer, respectively. Overall, patients were primarily older, white, had atrial fibrillation, and were dispensed dabigatran. After adjustment, there were no statistically significant differences in the primary outcome between the groups ( P > 0.05); however, concomitant inducer and DOAC use was associated with an increased risk of all-cause mortality ( P < 0.05).Conclusions: No excess risk of thrombosis during concomitant use of DOACs with CYP3A4/P-gp inducing antiseizure medications compared to use with gabapentin was identified. Further research is needed to confirm an association with excess all-cause mortality.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":"71-77"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venous thromboembolism secondary prophylaxis in elderly people (over 75 years old) with low-dose direct oral anticoagulants. 老年人静脉血栓栓塞二级预防（75岁以上）使用低剂量直接口服抗凝剂。

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-04-01 Epub Date: 2025-04-04 DOI: 10.1097/MBC.0000000000001350

Hinpetch Daungsupawong, Viroj Wiwanitkit

引用次数: 0

Coincidental occurrence of severe factor XII deficiency in a case of mild hemophilia A: a unique coagulation laboratory diagnostic conundrum. 巧合发生严重因子十二缺乏症的情况下，轻度血友病a：一个独特的凝血实验室诊断难题。

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-04-01 Epub Date: 2025-01-24 DOI: 10.1097/MBC.0000000000001346

Bipin P Kulkarni, Chandrakala Shanmukhaiah, Kirti Ghargi, Puloma Pandey, Shruti Kharat, Prachi Pawar, Sayali Shinde, Nikesh Kawankar, Sharda Shanbhag

引用次数: 0

Massive transfusion protocol prediction decision aids in an Australian trauma setting. 大规模输血方案预测决策辅助在澳大利亚创伤设置。

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-03-01 Epub Date: 2025-01-02 DOI: 10.1097/MBC.0000000000001338

Kush Wangoo, Vinh Dat David Nguyen, Karen Byth, Rajesh Malik, Andrew Coggins

{"title":"Massive transfusion protocol prediction decision aids in an Australian trauma setting.","authors":"Kush Wangoo, Vinh Dat David Nguyen, Karen Byth, Rajesh Malik, Andrew Coggins","doi":"10.1097/MBC.0000000000001338","DOIUrl":"10.1097/MBC.0000000000001338","url":null,"abstract":"Background: Trauma patients may require activation of an emergent massive transfusion protocol (MTP). Several decision aids are designed to predict massive transfusion requirements but have not been widely studied in the Australasian setting.Methods: Commonly used MTP decision aids were assessed for accuracy in injured patients at an urban Level 1 trauma centre. Consecutive cases were prospectively enrolled to a complete registry of thromboelastogram assays in trauma patients. Analysis was undertaken using receiver operating characteristic (ROC) curves, sensitivity and specificity.Results: A total of 114 patients met inclusion criteria (56 received MTP). More detailed and military derived scores including McLaughlin and Larson demonstrated >90% specificity. Area under ROC curve results were similar to prior reports, but the ABC score performed less accurately than expected.Conclusion: In the setting of traumatic haemorrhage, the available MTP prediction decision aids should be applied cautiously and used only in combination with on-going clinical judgement.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":"36 2","pages":"58-61"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as venous thromboembolism predictors in breast cancer patients pre- and post-therapy. 中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值作为乳腺癌患者治疗前后静脉血栓栓塞的预测因子的作用

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-03-01 Epub Date: 2025-01-02 DOI: 10.1097/MBC.0000000000001341

Alyssa Qian, Armita Zandi, Regan Bucciol, Maha Othman

{"title":"The role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as venous thromboembolism predictors in breast cancer patients pre- and post-therapy.","authors":"Alyssa Qian, Armita Zandi, Regan Bucciol, Maha Othman","doi":"10.1097/MBC.0000000000001341","DOIUrl":"10.1097/MBC.0000000000001341","url":null,"abstract":"Objectives: Breast cancer (BC) accounts for 12.3% of all cancer-associated venous thromboembolism (VTE). Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are recognized inflammatory biomarkers but have not been incorporated into thrombosis risk stratification models. We evaluated NLR and PLR as predictive biomarkers for VTE in BC patients to determine their optimal predictive cutoffs and net predictive value before and after treatment.Methods: We conducted a prospective pilot study that involved 56 women with BC, recruited prior to treatment (chemotherapy and immunotherapy) initiation with at least 6-month monitoring for VTE. NLR and PLR were assessed pre and posttreatment.Results: Five patients (8.9%) developed VTE. NLR and PLR increased significantly posttreatment (P = 0.001). Post, not pretreatment, NLR (P = 0.029) and PLR (P = 0.033) were significantly associated with VTE occurrence. Receiver Operating curve analysis indicated enhanced predictive capacity for VTE postimmunotherapy. Optimal posttreatment cutoffs were 3.6 for NLR and 280 for PLR, aligning with existing literature, with slightly elevated NLR.Conclusions: Posttreatment NLR and PLR have higher predictability for VTE in patients receiving immunotherapy compared to chemotherapy. NLR outperforms PLR, particularly postimmunotherapy. This data holds promise for thrombosis risk stratification in the context of immunotherapy but requires evaluation in larger studies.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":"36 2","pages":"62-67"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two patients with protein S deficiency and cerebral venous sinus thrombosis: nonsense mutations of the PROS1 gene may account for these deficiencies. 两例蛋白S缺乏和脑静脉窦血栓患者：PROS1基因的无义突变可能解释了这些缺陷。

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-03-01 Epub Date: 2025-01-02 DOI: 10.1097/MBC.0000000000001343

Lingling Hou, Xiaoli Chen, Haixiao Xie, Ke Zhang, Yanhui Jin, Minshan Wang, Lihong Yang, Fei Xu

{"title":"Two patients with protein S deficiency and cerebral venous sinus thrombosis: nonsense mutations of the PROS1 gene may account for these deficiencies.","authors":"Lingling Hou, Xiaoli Chen, Haixiao Xie, Ke Zhang, Yanhui Jin, Minshan Wang, Lihong Yang, Fei Xu","doi":"10.1097/MBC.0000000000001343","DOIUrl":"10.1097/MBC.0000000000001343","url":null,"abstract":"Cerebral venous sinus thrombosis (CVST) is a rare and atypical thrombotic condition, particularly prevalent among young adults, with a complex cause. In July and October 2023, two patients were diagnosed with hereditary protein S deficiency (PSD) presenting with CVST at the Department of Neurology, the first affiliated hospital of Wenzhou Medical University. This study analysed the phenotypes and gene mutations in two hereditary PSD pedigrees to investigate the link between hereditary PSD and CVST. A total of 11 individuals from these two pedigrees were involved. We measured protein S activity (PS:A) and total protein S antigen (TPS:Ag), and free protein S antigen (FPS:Ag) for all participants, screened them for mutations in the protein S1 (PROS1) gene. Both probands with CVST were diagnosed at a young to middle age. The concurrent reductions in PS:A, TPS:Ag, and FPS:Ag levels observed in the probands and their family members (A-I2, A-II1, A-II2, A-II3, A-III1, A-III2, B-I2) indicate type I PSD. Gene analysis unveiled two heterozygous nonsense mutations, c.1687C>T (p. Gln563∗) and c.1680T>A (p. Tyr560∗), in exon 14 of the PROS1 gene for pedigrees A and B, respectively. The reduced protein S levels in the probands and their relatives, along with CVST in both probands, are all linked to nonsense mutations p. Gln563∗ and p. Tyr560∗ in the PROS1 gene.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":"36 2","pages":"51-57"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare coagulation factor deficiencies: a five-year experience from a single tertiary care center in South India. 罕见凝血因子缺乏症：来自印度南部单一三级保健中心的五年经验。

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-03-01 Epub Date: 2025-01-10 DOI: 10.1097/MBC.0000000000001339

Nivedita Suresh, Bitty Kurian, Reshma Jeladharan, Amrita Sao, Neeraj Sidharthan, Reema Miria Abraham

{"title":"Rare coagulation factor deficiencies: a five-year experience from a single tertiary care center in South India.","authors":"Nivedita Suresh, Bitty Kurian, Reshma Jeladharan, Amrita Sao, Neeraj Sidharthan, Reema Miria Abraham","doi":"10.1097/MBC.0000000000001339","DOIUrl":"10.1097/MBC.0000000000001339","url":null,"abstract":"Objective: Rare coagulation factor deficiencies (RCFD) comprise a heterogeneous class of coagulation disorders due to deficiencies/abnormalities in coagulation factors other than factors VIII, IX and von Willebrand factor (VWF). Due to its rarity and varying geographic prevalence, bleeding characteristics and behaviour pattern are not known. Our aim was to study the frequency and clinical profile of RCFD, assess the severity of deficiency, evaluate blood component requirements and surgical outcomes.Methods: This is a retrospective cohort study done at Advanced Coagulation Laboratory, Amrita Hospital, Kerala from September 2018 to October 2023. Clinical characteristics including bleeding phenotype were noted. The patients were diagnosed based on their complete coagulation workup.Results: Total of 1019 patients were evaluated, 93 (9.1%) patients had RCFD. Males and females were 60 (64.5%) and 33 (35.5%), respectively (M : F ratio 2 : 1). Median age at diagnosis was 26 years (range: 2 months-74 years). Half the patients (47) had bleeding episodes, 23 (25%) patients were detected incidentally and 23 (25%) patients as a part of preoperative evaluation. Mucocutaneous bleeding was the commonest symptom. The most common RCFD was factor VII deficiency (40%). Transfusion/hemostatic support was required for 29 (31.2%) patients during their life time. No adverse outcome was noted in 27 (29%) patients who underwent surgeries.Conclusion: Factor VII deficiency was the commonest RCFD. Only half of the patients with RCFD were symptomatic. RCFDs generally have a favorable surgical/ pregnancy outcome. Data from resource limited settings are lacking; more studies are required to formulate management guidelines.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":"36 2","pages":"37-43"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Compound heterozygous mutations (p.L68R∗37 and p.T241N) lead to abnormal protein levels and structures in hereditary FVII deficiency. 复合杂合突变（p.L68R * 37和p.T241N）导致遗传性FVII缺乏的蛋白水平和结构异常。

IF 1.2 4区医学

Blood Coagulation & Fibrinolysis Pub Date : 2025-03-01 Epub Date: 2025-01-06 DOI: 10.1097/MBC.0000000000001340

Bingqing Luo, Xia Wu, Jing Zhu, Shu Chen, Shifeng Lou, Xiaoyan Tan

{"title":"Compound heterozygous mutations (p.L68R∗37 and p.T241N) lead to abnormal protein levels and structures in hereditary FVII deficiency.","authors":"Bingqing Luo, Xia Wu, Jing Zhu, Shu Chen, Shifeng Lou, Xiaoyan Tan","doi":"10.1097/MBC.0000000000001340","DOIUrl":"10.1097/MBC.0000000000001340","url":null,"abstract":"Background: Congenital factor VII (FVII) deficiency is a genetic disorder characterized by decreased FVII activity, which sometimes leads to fatal bleeding. Numerous variants have been found in FVII deficiency, but mutations vary among patients. Each mutation deserves further exploration for each patient at risk of bleeding. We previously reported a Chinese patient with p.L68R∗37 and p.T241N compound heterozygous mutations. In this study, we further investigated the impact of these two mutations on the FVII expression through in vitro expression experiments.Methods: Mutations were introduced into the FVII coding region using site-directed mutagenesis, and recombinant FVII was combined with two different plasmids, and then quantitative PCR and western blot analyses were performed subsequently.Results: The p.L68R∗37 mutation had no effect on mRNA levels but caused a significant decrease in protein levels. In the p.T241N mutant vector, mRNA levels did not show a noticeable decrease, but protein levels exhibited a slight decrease. Structural analysis revealed that the p.T241N mutation resulted in an altered secondary structure and protein instability, indicating impaired functional properties.Conclusion: Our study demonstrated that the p.L68R∗37 and p.T241N mutations impacted the protein levels and function of FVII, ultimately leading to a severe reduction in FVII activity. This study may contribute to further understanding of the molecular pathogenesis of FVII deficiency and offer insights for genetic counseling.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":"44-50"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0